Literature DB >> 12473573

Testing of new agents in childhood cancer preclinical models: meeting summary.

Peter J Houghton1, Peter C Adamson, Susan Blaney, Howard A Fine, Richard Gorlick, Michelle Haber, Lee Helman, Steve Hirschfeld, Melinda G Hollingshead, Mark A Israel, Richard B Lock, John M Maris, Glenn Merlino, Wendy Patterson, C Patrick Reynolds, Kevin Shannon, Alice Yu, John Yu, Malcolm A Smith.   

Abstract

A workshop on pediatric preclinical testing, sponsored by the National Cancer Institute and the Children's Oncology Group Phase 1 Consortium, was held on June 26-27, 2001 in Bethesda, Maryland. Drs. Peter Adamson, Peter Houghton, and Malcolm Smith organized and hosted the meeting. There were 20 participants from 12 institutions. The primary objectives of the workshop included: (a) development of a working inventory of available preclinical models (including human tumor xenografts in immunodeficient mice, transgenic and syngeneic tumors, and selected in vitro models), with a basic understanding of the strengths and weaknesses of each as possible components of a preclinical testing program; (b) identification of the key scientific issues related to establishment of a program for preclinical testing of new agents for their applicability to childhood cancers; and (c) identification of the key infrastructure requirements for a program for preclinical testing of new agents for their applicability to childhood cancers. This report is a synthesis of the workshop's presentations and discussions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473573

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  19 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Balancing safety, effectiveness, and public desire: the FDA and cancer.

Authors:  Rena Conti
Journal:  Issue Brief (Commonw Fund)       Date:  2003-04

Review 3.  Challenges and Opportunities for Childhood Cancer Drug Development.

Authors:  Peter J Houghton; Raushan T Kurmasheva
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 4.  A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program.

Authors:  L Jones; H Carol; K Evans; J Richmond; P J Houghton; M A Smith; R B Lock
Journal:  Leukemia       Date:  2016-07-15       Impact factor: 11.528

Review 5.  Pharmacokinetic/ pharmacodynamic-driven drug development.

Authors:  James M Gallo
Journal:  Mt Sinai J Med       Date:  2010 Jul-Aug

6.  Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy.

Authors:  Su Guan; Ruijun Shen; Tiffany Lafortune; Ningyi Tiao; Peter Houghton; W K Alfred Yung; Dimpy Koul
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

7.  Evaluation of ABT-751 against childhood cancer models in vivo.

Authors:  Christopher L Morton; Edward G Favours; Kimberly S Mercer; Claire R Boltz; Jeri Carol Crumpton; Chandra Tucker; Catherine A Billups; Peter J Houghton
Journal:  Invest New Drugs       Date:  2007-03-24       Impact factor: 3.850

8.  Morphologic and molecular characterization of ATRT xenografts adapted for orthotopic therapeutic testing.

Authors:  Rintaro Hashizume; Nalin Gupta; Mitchel S Berger; Anu Banerjee; Michael D Prados; Jennifer Ayers-Ringler; C David James; Scott R VandenBerg
Journal:  Neuro Oncol       Date:  2010-01-11       Impact factor: 12.300

9.  Characterization of 2 Novel Ependymoma Cell Lines With Chromosome 1q Gain Derived From Posterior Fossa Tumors of Childhood.

Authors:  Vladimir Amani; Andrew M Donson; Seth C Lummus; Eric W Prince; Andrea M Griesinger; Davis A Witt; Todd C Hankinson; Michael H Handler; Kathleen Dorris; Rajeev Vibhakar; Nicholas K Foreman; Lindsey M Hoffman
Journal:  J Neuropathol Exp Neurol       Date:  2017-07-01       Impact factor: 3.685

10.  Molecular characterization of the pediatric preclinical testing panel.

Authors:  Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; C Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey Dome; Joseph Khoury; Timothy J Triche; Robert C Seeger; Richard Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.